Increased Transparency of Drug Research Costs: New Disclosure Rules for Pharma.
This Act mandates the public disclosure of detailed costs associated with drug clinical trials and overall research and development (R&D) expenditures. Pharmaceutical companies must post data on total trial costs, including personnel and supply expenses, on a new, publicly accessible federal website. Furthermore, drug manufacturers must report their total R&D spending, broken down by development stage, in their annual financial reports, aiming to provide citizens with greater clarity on drug pricing.
Key points
Creation of a public federal website (repository) dedicated to disclosing the detailed costs of drug clinical trials for public review.
Drug companies must post detailed clinical trial costs (e.g., cost per patient, expenses for personnel and equipment) within one year of trial completion.
Publicly traded drug manufacturers must report total R&D expenditures, disaggregated by research phase (e.g., pre-clinical, Phase I, II, III), in SEC filings.
Expired
Citizen Poll